S&P 500   3,398.86 (-0.06%)
DOW   27,553.66 (-0.48%)
QQQ   282.09 (+0.58%)
AAPL   116.28 (+1.07%)
MSFT   213.74 (+1.74%)
FB   283.00 (+2.13%)
GOOGL   1,592.29 (+0.50%)
AMZN   3,273.50 (+2.07%)
TSLA   422.36 (+0.49%)
NVDA   532.80 (+1.36%)
BABA   317.72 (+3.54%)
CGC   18.74 (+1.13%)
GE   7.18 (-2.71%)
MU   52.06 (-0.15%)
AMD   78.17 (-4.94%)
T   27.06 (-1.17%)
F   7.96 (-0.87%)
ACB   4.07 (-7.50%)
GILD   59.90 (-0.10%)
NFLX   487.17 (-0.22%)
NIO   27.86 (+7.11%)
BA   156.44 (-2.73%)
DIS   123.59 (-0.38%)
S&P 500   3,398.86 (-0.06%)
DOW   27,553.66 (-0.48%)
QQQ   282.09 (+0.58%)
AAPL   116.28 (+1.07%)
MSFT   213.74 (+1.74%)
FB   283.00 (+2.13%)
GOOGL   1,592.29 (+0.50%)
AMZN   3,273.50 (+2.07%)
TSLA   422.36 (+0.49%)
NVDA   532.80 (+1.36%)
BABA   317.72 (+3.54%)
CGC   18.74 (+1.13%)
GE   7.18 (-2.71%)
MU   52.06 (-0.15%)
AMD   78.17 (-4.94%)
T   27.06 (-1.17%)
F   7.96 (-0.87%)
ACB   4.07 (-7.50%)
GILD   59.90 (-0.10%)
NFLX   487.17 (-0.22%)
NIO   27.86 (+7.11%)
BA   156.44 (-2.73%)
DIS   123.59 (-0.38%)
S&P 500   3,398.86 (-0.06%)
DOW   27,553.66 (-0.48%)
QQQ   282.09 (+0.58%)
AAPL   116.28 (+1.07%)
MSFT   213.74 (+1.74%)
FB   283.00 (+2.13%)
GOOGL   1,592.29 (+0.50%)
AMZN   3,273.50 (+2.07%)
TSLA   422.36 (+0.49%)
NVDA   532.80 (+1.36%)
BABA   317.72 (+3.54%)
CGC   18.74 (+1.13%)
GE   7.18 (-2.71%)
MU   52.06 (-0.15%)
AMD   78.17 (-4.94%)
T   27.06 (-1.17%)
F   7.96 (-0.87%)
ACB   4.07 (-7.50%)
GILD   59.90 (-0.10%)
NFLX   487.17 (-0.22%)
NIO   27.86 (+7.11%)
BA   156.44 (-2.73%)
DIS   123.59 (-0.38%)
S&P 500   3,398.86 (-0.06%)
DOW   27,553.66 (-0.48%)
QQQ   282.09 (+0.58%)
AAPL   116.28 (+1.07%)
MSFT   213.74 (+1.74%)
FB   283.00 (+2.13%)
GOOGL   1,592.29 (+0.50%)
AMZN   3,273.50 (+2.07%)
TSLA   422.36 (+0.49%)
NVDA   532.80 (+1.36%)
BABA   317.72 (+3.54%)
CGC   18.74 (+1.13%)
GE   7.18 (-2.71%)
MU   52.06 (-0.15%)
AMD   78.17 (-4.94%)
T   27.06 (-1.17%)
F   7.96 (-0.87%)
ACB   4.07 (-7.50%)
GILD   59.90 (-0.10%)
NFLX   487.17 (-0.22%)
NIO   27.86 (+7.11%)
BA   156.44 (-2.73%)
DIS   123.59 (-0.38%)
Log in
NASDAQ:RPRX

Royalty Pharma Stock Forecast, Price & News

$38.15
-0.62 (-1.60 %)
(As of 10/27/2020 02:26 PM ET)
Add
Compare
Today's Range
$37.68
Now: $38.15
$38.98
50-Day Range
$38.56
MA: $41.29
$44.81
52-Week Range
$38.10
Now: $38.15
$56.50
Volume34,782 shs
Average Volume1.57 million shs
Market Capitalization$13.96 billion
P/E RatioN/A
Dividend Yield1.54%
BetaN/A
Royalty Pharma plc operates in the biopharmaceutical industry. The company operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry. It is involved in the identification, evaluation, and acquisition of royalties and royalty-related assets on various biopharmaceutical therapies. The company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies. Its portfolio includes royalties on approximately 45 commercial products and three development-stage product candidates. The company has royalties on various therapeutic areas and drug classes, including Neulasta, Neupogen, Rituxan, Imbruvica, Trodelvy, Tazverik, and Xtandi in oncology; Lyrica in neuropathic pain; Biktarvy, Genvoya, Prezista, Symtuza, Truvada, and Atripla in HIV; Humira, Remicade, and Cimzia TNF inhibitors; Kalydeco, Orkambi, Symdeko, and Trikafta in cystic fibrosis; Tecfidera and Tysabri in multiple sclerosis; Emgality, Nurtec ODT (rimegepant), and vazegepant in migraine; and others. Royalty Pharma plc was founded in 1996 and is based in New York, New York.
Read More
Royalty Pharma logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.2Community Rank: 2.7Dividend Strength: 1.7Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.84 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorFinance
Current SymbolNASDAQ:RPRX
CUSIP76028H20
Phone212-883-0200
EmployeesN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

Market Cap$13.96 billion
Next Earnings Date11/11/2020 (Confirmed)
OptionableNot Optionable
$38.15
-0.62 (-1.60 %)
(As of 10/27/2020 02:26 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RPRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RPRX and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Royalty Pharma (NASDAQ:RPRX) Frequently Asked Questions

Do Wall Street analysts recommend investors buy shares of Royalty Pharma?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Royalty Pharma in the last year. There are currently 6 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for Royalty Pharma
.

When is Royalty Pharma's next earnings date?

Royalty Pharma is scheduled to release its next quarterly earnings announcement on Wednesday, November 11th 2020.
View our earnings forecast for Royalty Pharma
.

How can I listen to Royalty Pharma's earnings call?

Royalty Pharma will be holding an earnings conference call on Wednesday, November 11th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Royalty Pharma's earnings last quarter?

Royalty Pharma plc (NASDAQ:RPRX) released its quarterly earnings data on Wednesday, August, 12th. The biopharmaceutical company reported $0.73 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $0.61 by $0.12. The biopharmaceutical company earned $511 million during the quarter, compared to analyst estimates of $509.88 million.
View Royalty Pharma's earnings history
.

How often does Royalty Pharma pay dividends? What is the dividend yield for Royalty Pharma?

Royalty Pharma declared a quarterly dividend on Friday, October 16th. Stockholders of record on Friday, November 20th will be paid a dividend of $0.15 per share on Tuesday, December 15th. This represents a $0.60 dividend on an annualized basis and a yield of 1.58%. The ex-dividend date is Thursday, November 19th.
View Royalty Pharma's dividend history
.

What price target have analysts set for RPRX?

10 Wall Street analysts have issued 1-year price targets for Royalty Pharma's stock. Their forecasts range from $47.00 to $56.00. On average, they anticipate Royalty Pharma's stock price to reach $52.33 in the next year. This suggests a possible upside of 38.1% from the stock's current price.
View analysts' price targets for Royalty Pharma
.

Who are some of Royalty Pharma's key competitors?

What other stocks do shareholders of Royalty Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Royalty Pharma investors own include Twitter (TWTR), Bausch Health Companies (BHC), NVIDIA (NVDA), Relypsa (RLYP), Aeterna Zentaris (AEZS), Advanced Micro Devices (AMD), Netflix (NFLX), QUALCOMM (QCOM), salesforce.com (CRM) and Twilio (TWLO).

Who are Royalty Pharma's key executives?

Royalty Pharma's management team includes the following people:
  • Mr. Pablo G. Legorreta, Founder, Chairman & CEO (Age 56, Pay $28.55M)
  • Mr. Terrance P. Coyne, Exec. VP & CFO
  • Mr. George W. Lloyd, Exec. VP of Investments & Gen. Counsel (Age 61, Pay $2.18M)
  • Dr. James F. Reddoch Ph.D., Exec. VP of Research & Investments (Age 50, Pay $2.08M)
  • Mr. Christopher Hite, Vice Chairman & Exec. VP (Age 53)

When did Royalty Pharma IPO?

(RPRX) raised $1.9 billion in an initial public offering (IPO) on Tuesday, June 16th 2020. The company issued 70,000,000 shares at $25.00-$28.00 per share. J.P. Morgan, Morgan Stanley, BofA Securities, Goldman Sachs, Citigroup and UBS Investment Bank served as the underwriters for the IPO and Evercore ISI, Cowen and SunTrust Robinson Humphrey were co-managers.

What is Royalty Pharma's stock symbol?

Royalty Pharma trades on the NASDAQ under the ticker symbol "RPRX."

When does the company's lock-up period expire?

Royalty Pharma's lock-up period expires on Monday, December 14th. Royalty Pharma had issued 77,681,670 shares in its initial public offering on June 16th. The total size of the offering was $2,175,086,760 based on an initial share price of $28.00. After the end of the company's lock-up period, major shareholders and company insiders will be able to sell their shares of the company.

Who are Royalty Pharma's major shareholders?

Royalty Pharma's stock is owned by many different retail and institutional investors. Top institutional investors include Avitas Wealth Management LLC (0.01%). Company insiders that own Royalty Pharma stock include Adage Capital Partners Gp, LL, George W Lloyd, Pablo G Legorreta, Rory B Riggs, Terrance P Coyne and William E Ford.
View institutional ownership trends for Royalty Pharma
.

Which major investors are buying Royalty Pharma stock?

RPRX stock was acquired by a variety of institutional investors in the last quarter, including Avitas Wealth Management LLC. Company insiders that have bought Royalty Pharma stock in the last two years include Adage Capital Partners Gp, LL, George W Lloyd, Pablo G Legorreta, Terrance P Coyne, and William E Ford.
View insider buying and selling activity for Royalty Pharma
.

How do I buy shares of Royalty Pharma?

Shares of RPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Royalty Pharma's stock price today?

One share of RPRX stock can currently be purchased for approximately $37.90.

How big of a company is Royalty Pharma?

Royalty Pharma has a market capitalization of $13.87 billion.

What is Royalty Pharma's official website?

The official website for Royalty Pharma is www.royaltypharma.com.

How can I contact Royalty Pharma?

Royalty Pharma's mailing address is 110 E 59th Street, New York NY, 10022. The biopharmaceutical company can be reached via phone at 212-883-0200 or via email at [email protected]

This page was last updated on 10/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.